MedTrace Logo

Internet-based Treatment for Provoked Vestibulodynia

NCT04045041 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-12-27

No results posted yet for this study

Summary

Provoked vestibulodynia is a pain condition, which is associated with lower quality of life and discomfort. Furthermore, it is underdiagnosed and undertreated. Provoked vestibulodynia is defined as vulvar pain with no known cause. Provoked vestibulodynia can be generalized and involve several areas of the vulva. It can also be localized and involve only one area of the vulva. Pain is often provoked by touch or pressure but it can also be spontaneous or both. The life prevalence for vestibulodynia varies between 3-28 percent in different populations. Persons with vestibulodynia report more frequently anxiety-, depression- and stress- symptoms than the normal population.

The aim of the present study is to evaluate an internet-based treatment for vestibulodynia. The intervention will be based on Acceptance and commitment therapy (ACT) and cognitive behavior therapy with focus on exposure and acceptance.

Conditions

  • Provoked Vestibulodynia
  • Vulvodynia, Generalized

Interventions

BEHAVIORAL

Acceptance and commitment therapy

An acceptance based intervention with focus on exposure.

Sponsors & Collaborators

  • Uppsala University

    lead OTHER

Principal Investigators

  • Monica Buhrman, PhD · Uppsala University

  • Lance McCracken, Professor · Uppsala University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-20
Primary Completion
2020-12-30
Completion
2021-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04045041 on ClinicalTrials.gov